2nd Hippo Pathway Targeted Drug Development Summit 2023
Bringing Clinically Validated TEAD, YAP & TAZ Modulators to Patients Faster
The 2nd Hippo Pathway Targeted Drug Development Summit was the first and only industry-led forum, uniting a community focussed on progressing the functional understanding and realizing the potential of the Hippo signaling pathway to enhance the discovery, translation and clinical development of safe and effective drugs in oncology, regenerative medicine and beyond.
Welcoming a host of exciting new Hippo Pathway leaders like YAP Therapeutics, BeacticaAB, and Sporos Bioventures
Broadening the Hippo pathway toolbelt with discussions beyond TEAD Palmitoylation inhibition, in areas like TPD and YAP/TAZ modulation with talks from Harvard Medical Universityand Stanford.
Exploring commonly shared struggles such as identification of biomarkers, characterization of TEAD isoformsfor specificity all with the aim of subverting toxicity